Royalty Report: Diagnostic, Cancer, Medical – Collection: 7158

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Diagnostic
  • Cancer
  • Medical
  • Drugs
  • Disease
  • Biotechnology
  • Device
  • Software
  • Medical Info
  • Diagnostic Substances
  • Proteins
  • Assay
  • Technical Know How
  • cardiac
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7158

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee accepts the licenses under the Licensed Technology to exclusively use, develop, make, have made, sell, offer to sell, modify, import and otherwise commercially exploit the Licensed Uses and the Licensed Products in the Licensed Territory including, but not limited to, as follows
(1) an exclusive license for the use of the SVM Technology and the Licensed Patents in the Field in the Licensed Territory relating to Licensed Uses and Licensed Products; and

(2) an exclusive license to the Licensed Know-How in the Field in the Licensed Territory, including access to and use of the Computer Software that has been developed by or for Licensor or will be developed by or for the Licensor that may be applicable to Licensed Uses or Licensed Products; and

(3) an exclusive license for the use of Licensed Products in the Licensed Territory.
Sublicense Rights. Licensee may grant sublicenses under any of the licenses granted herein, to import, develop, make, have made, use, modify, offer for sale, and/or sell Licensed Products within the Field.

License Property
LICENSOR is the owner of intellectual property, including patents, pending and issued, and know-how relating to support vector machine and other machine learning technologies which is included within the “SVM Technology” (as defined below), based upon which it has developed, or is engaged in developing, applications including, inter alia, digital image analysis and interpretation, biomarker discovery, and gene/gene product-based and protein-based diagnostic, prognostic and predictive tests.

“SVM Technology” shall mean all technology and ownership claims related to support vector machines and other pattern-recognition algorithms (“SVM”), SVM-Recursive Feature Elimination (“RFE”), and Fractal Genomic Modelling (“FGM”) included in the Licensed Technology.

Licensor owns the Licensed Technology (as defined below), which includes inter alia, coverage of genomic biomarkers related to prostate cancer, pancreatic cancer, colon cancer and other cancers as well as certain interpretation methodologies and software associated with automated image analysis for cytogenetics and flow cytometry testing.

“IVD Test Kit” shall mean any kit or instrument manufactured for sale to third parties, which includes reagents and other supplies that enables such third party purchasers to perform in vitro diagnostic tests on biological samples or any instrument used therewith; provided that, any such IVD Test Kit must be approved by the U.S. Food and Drug Administration (“FDA”) for sales of the IVD Test Kit in the United States, or be approved by any other foreign regulatory bodies for sales of the IVD Test Kit in countries other than the United States. Notwithstanding the foregoing, any instruments sold in conjunction with or pursuant to Licenses E and F described in Sections 1.12.4 and 1.12.5 are excluded from the definition of IVD Test Kit.

“Laboratory Developed Test” shall mean any test, process or procedure used to test or assay any type of patient biological sample, the results of which would then normally be entered into the medical record of the patient providing such biological sample; provided, however, any test, process or procedure performed using an IVD Test Kit shall not be considered to be a Laboratory Developed Test.

“Plasma Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in blood plasma for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Plasma Prostate Cancer Test is identified as “License B”.

“Pancreatic Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in any type of biological sample for differentiating clinically significant pancreatic cancer from other pancreatic conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Pancreatic Test is identified as “License C”.

“Colon Cancer Test” shall mean any Laboratory Developed Test using genes, gene products or other biomarkers for differentiating clinically significant colon cancer from other colon conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Colon Cancer Test is identified as “License D”.

“Cytogenetics Interpretation System” shall mean any interpretive software and related technology for computer-aided karyotype analysis for genetic screening and detection of chromosomal abnormalities. For reference purposes, the license granted for the Cytogenetics Interpretation System is identified as “License E”.

“Flow Cytometry Interpretation System” shall mean interpretive software and related technology for computer-aided analysis of flow cytometry tests. For reference purposes, the license granted for the Flow Cytometry Interpretation System is identified as “License F”.

“Urine Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in urine samples for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Urine Prostate Cancer Test is identified as “License G”.

“Tissue Prostate Cancer Test” shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in tissue samples for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Tissue Prostate Cancer Test is identified as “License H”.

Licensed Patents
Patent/Application No.
Title
Filing Date/
Expires

Issue Date

Patent/Application No.
Title
Filing Date/
Expires

Issue Date

U.S. Patent No. 6,128,608
Enhancing Knowledge Discovery Using Multiple Support Vector Machines
05-01-1999/
5/1/2019

10/3/2000

U.S. Patent No. 6,157,921
Enhancing Knowledge Discovery Using Support Vector Machines in a Distributed Network Environment
05-01-1999/
5/1/2019

12/5/2000

U.S. Patent No. 6,427,141
Enhancing Knowledge Discovery Using Multiple Support Vector Machines.
05-09-2000/
5/1/2019

7/30/2002

U.S. Patent No. 6,658,395
Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.
05-24-2000/
5/1/2019

12/2/2003

U.S. Patent No. 6,714,925
System for Identifying Patterns in Biological Data Using a Distributed Network.
08-07-2000/
5/1/2019

3/30/2004

U.S. Patent No. 6,760,715
Enhancing Biological Knowledge Discovery Using Multiple Support Vector Machines.
08-07-2000/
5/1/2019

7/6/2004

U.S. Patent No. 6,789,069
Method of Identifying Patterns in Biological Systems and Method of Uses.
08-07-2000/
4/13/2020

9/7/2004

U.S. Patent No. 6,882,990
Method of Identifying Biological Patterns Using Multiple Data Sets.
08-07-2000/
5/1/2019

4/19/2005

U.S. Patent No. 6,944,602
Spectral Kernels for Learning Machines
03-01-2002/
2/19/2023

9/13/2005

U.S. Patent No. 6,996,549
Computer-Aided Image Analysis
01-23-2002/
4/21/2021

2/7/2006

U.S. Patent No. 7,117,188
Methods of Identifying Patterns in Biological Systems and Uses Thereof
01-24-2002/
3/9/2022

10/3/2006

U.S. Patent No. 7,299,213
Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset
09-12-2005/
3/1/2022

11/20/2007

U.S. Patent No. 7,318,051
Methods for Feature Selection in a Learning Machine
11-18-2003/
2/25/2021

1/8/2008

U.S. Patent No. 7,353,215
Kernels and Methods for Selecting Kernels for Use in Learning Machines
11-07-2003/
1/27/2023

4/1/2008

U.S. Patent No. 7,383,237
Computer-Aided Image Analysis
02-06-2006/
11/4/2019

6/3/2008

U.S. Patent No. 7,444,308
Data Mining Platform for Bioinformatics and Other Knowledge Discovery
12-15-2003/
5/28/2022

10/28/2008

U.S. Patent No. 7,475,048
Pre-Processed Feature Ranking for a Support Vector Machine
05-07-2004/
7/22/2021

1/6/2009

U.S. Patent No. 7,542,947
Data Mining Platform for Bioinformatics and Other Knowledge Discovery
10-30-2007/
5/20/2022

6/2/2009

U.S. Patent No. 7,542,959
Feature Selection Method Using Support Vector Machine Classifier
08-21-2007/
8/7/2020

6/2/2009

U.S. Patent No.  7,617,163
Kernels and Kernel Methods for Spectral Data
10-09-2002/

11/10/2009

U.S. Patent No. 7,624,074
Methods for Feature Selection in a Learning Machine
10-30-2007/
8/7/2020

11/24/2009

U.S. Patent No. 7,676,442
Selection of Features Predictive of Biological Conditions Using Protein Mass Spectrographic Data
10-30-2007/
8/7/2020

3/9/2010

U.S. Patent No. 7,788,193
Kernels and Methods for Selecting Kernels for Use in Learning Machines
10-30-2007/
8/6/2023

8/31/2010

U.S. Patent No. 7,797,257
System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source
10-31-2007/
7/28/2020

9/14/2010

U.S. Patent No. 7,805,388
Method for Feature Selection in a Support Vector Machine Using Feature Ranking
10-30-2007/
8/7/2020

9/28/2010

U.S. Patent No. 7,890,445
Model Selection for Cluster Data Analysis
10-30-2007/
6/8/2024

12/15/2011

U.S. Patent No.  7,921,068
Data Mining Platform for Knowledge Discovery from Heterogeneous Data Types and/or Heterogeneous Data Sources
10-30-2007/
5/20/2022

4/5/2011

U.S. Patent No.  7,970,718
Method for Feature Selection and for Evaluating Features Identified as Significant for Classifying Data
09-26-2010/
1/24/2022

6/28/2011

U.S. Patent No.  8,008,012
Biomarkers Downregulated in Prostate Cancer
09-30-2008/
1/13/2026

8/30/2011

U.S. Patent  No. 8,095,483
Support Vector Machine-Recursive Feature Elimination (SVM-RFE)
12-01-2010/
8/7/2020

1/10/2012

U.S. Patent Publ. No. 2005/0165556
Colon Cancer-Specific Biomarkers
01-11-2005/
08-07-2020 + PTA

U.S. Patent Publ. No. 2010/0256988
System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source
06-11-2010/
5/1/2019

U.S. Patent Publ. No. 2011/0106735
Recursive Feature Elimination Method Using Support Vector Machines
11/11/2010
08-07-2020 + PTA

U.S.Patent Publ. No. 2010/0318482
Kernels for Identifying Patterns in Datasets Containing Noise or Transformation Invariances
08-25-2010/
05-07-2022 + PTA

U.S.Patent Publ. No. 2011/0184896
Method for Visualizing Feature Ranking of a Subset of Features for Classifying Data Using a Support Vector Machine
04-04-2011/
05-20-2022  PTA

U.S. Patent Publ. No. 2010/0205124
Support Vector Machine-Based Method for Analysis of Spectral Data
02-04-2010/
08-07-2020 + PTA

U.S.Patent Publ. No. 2011/0125683
Identification of Co-Regulation Patterns by Unsupervised Cluster Analysis of Gene Expression Data
02-02-2011/
05-17-2022 + PTA

U.S. Patent Publication No. 2009/0204557
Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines
02-08-2009/
02-08-2029 + PTA

U.S. Patent Publication No. 2008/0050836
Biomarkers for Screening, Predicting, and Monitoring Benign Prostate Hyperplasia
07-26-2007/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0215024
Biomarkers Upregulated in Prostate Cancer
02-04-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0286240
Biomarkers Overexpressed in Prostate Cancer
09-30-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0215058
Methods for Screening, Predicting and Monitoring Prostate Cancer
12-04-2008/
11-14-2025 + PTA

U.S. Patent Publication No. 2009/0226915
Methods for Screening, Predicting and Monitoring Prostate Cancer
01-06-2009/
11-14-2025 + PTA

U.S.Patent Publication No.  2011/0312509
Biomarkers Downregulated in Prostate Cancer
08-29-2011/
11-14-2025 + PTA

U.S. Patent No. 6,920,451
Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets
01-19-2001/
6/9/2021

7/19/2005

U.S. Patent No. 7,366,719
Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets
10-06-2004/

4/29/2008

Field of Use
“Field” or “Field of Use” shall mean the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology, and digital image analysis, excluding non-pathology-related radiologic and photographic image analysis, relating to the development, marketing, production or sale of any Laboratory Developed Tests or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer; provided, however, the manufacture and sale of IVD Test Kits for sales to third parties and the melanoma screening system and methods described in the patent applications listed in Exhibit D are specifically excluded from the Field or Field of Use; and provided further that the foregoing exclusion of “and breast cancer” immediately prior to the first proviso of this section shall be in effect only so long as the License Agreement among and between LICENSOR.

The Licensee is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. The Licensee's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, The Licensee services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States.

IPSCIO Record ID: 3784

License Grant
Licensor hereby grants to Licensee an exclusive License to the Licensed Technology, including the right to make, have made, use, import, distribute, and sell any Licensed Product in the Field of Use within the Licensed Territory.
License Property
Licensor has certain patent rights and technology covering systems and methods for enhancing knowledge discovered from data using learning machines in general and Support Vector Machines (SVM).

“Licensed Product” shall mean a product, including, but not limited to, devices, diagnostic kits, prognostic kits, test reagents, research reagents, proprietary compositions, substances, methods, documentation, software, services or a part thereof, the manufacture, use, sale, offer to sell, importation, distribution, or transfer.

Licensor developed a superior breast cancer prognostic test using the licensor's support vector machine (SVM) technology.  The work will be done in collaboration with a medical Cancer Center.  

Patent/Application No.

Title

U.S. Patent No. 6,128,608

Enhancing Knowledge Discovery Using Multiple Support Vector Machines

U.S. Patent No. 6,157,921

Enhancing Knowledge Discovery Using Support Vector Machines in a Distributed Network Environment

U.S. Patent No. 6,427,141

Enhancing Knowledge Discovery Using Multiple Support Vector Machines.

U.S. Patent No. 6,658,395

Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.

U.S. Patent No. 6,714,925

System for Identifying Patterns in Biological Data Using a Distributed Network.

U.S. Patent No. 6,760,715

Enhancing Biological Knowledge Discovery Using Multiple Support Vector Machines.

U.S. Patent No. 6,789,069

Method of Identifying Patterns in Biological Systems and Method of Uses.

U.S. Patent No. 6,882,990

Method of Identifying Biological Patterns Using Multiple Data Sets.

U.S. Patent No. 6,944,602

Spectral Kernels for Learning Machines

U.S. Patent No. 6,996,542

Computer-Aided Image Analysis

U.S. Patent No. 7,117,188

Methods of Identifying Patterns in Biological Systems and Uses Thereof

U.S. Patent No. 7,299,213

Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset

U.S. Patent No. 7,318,051

Methods for Feature Selection in a Learning Machine

U.S. Patent No. 7,353,215

Kernels and Methods for Selecting Kernels for Use in a Learning Machine

U.S. Patent No. 7,383,237

Computer-Aided Image Analysis

U.S. Patent Publication No. 2008/0059392

System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source

U.S. Patent Publication No. 2008/0033899

Feature Selection Using Support Vector Machine Classifier

U.S. Application No. 11/929,213

Methods for Feature Selection in a Learning Machine

U.S. Patent Publication No. 2005/0071140

Model Selection for Cluster Data Analysis

U.S. Patent Publication No. 2008/0140592

Model Selection for Cluster Data Analysis

U.S. Patent Publication No. 2006/0064415

Data Mining Platform for Bioinformatics

U.S. Patent Publication No. 2008/0097938

Data Mining Platform for Knowledge Discovery from Heterogeneous Data Types and/or Heterogeneous Data Sources

U.S. Patent Publication No. 2008/0097939

Data Mining Platform for Bioinformatics

U.S. Patent Publication No. 2005/0228591

Kernels and Kernel Methods for Spectral Data

U.S. Patent Publication No. 2008/0097940

Kernels and Kernel Methods for Spectral Data

U.S. Patent Publication No. 2005/0131847

Pre-Processed Feature Ranking for a Support Vector Machine

U.S. Application No. 11/928,784

Pre-Processed Feature Ranking for a Support Vector Machine

U.S. Application No. 11/929,354

Kernels and Methods for Selecting Kernels for Use in a Learning Machine

U.S. Provisional Application No. 61/027,416

Analysis of Flow Cytometry Data Using Support Vector Machines

Field of Use
“Field of Use” shall mean diagnostic, prognostic, or predictive tests related to breast cancer, and/or the choice of therapeutic agents for improving the clinical outcome of breast cancer, such tests based on data obtained from any source or analysis, including, but not limited to, biopsied breast tissue, plasma, imaging analysis, or other means of assessing a patient for breast cancer, whether invasive or noninvasive.

IPSCIO Record ID: 4014

License Grant
Licensor hereby grants to Licensee a co-exclusive sublicense to utilize the Licensed Patent Rights to the extent necessary to enable Licensee to perform its obligations to develop the Product(s) and perform the Validation Work under the Development Agreement (the “Development License”).
License Property
Licensor is the owner of intellectual property, including patents, pending and issued, and know-how, all relating to support vector machine (“SVM”) and other learning machine technology, based upon which it has developed, or is engaged in developing, applications including, inter alia, digital image analysis, biomarker discovery, and gene- and protein-based diagnostic and prognostic testing

Machine learning is a type of artificial intelligence that enables the development of algorithms and techniques that allow computers to learn.

Licensed Patent Rights
U.S. Patent No. 6,128,608
Enhancing Knowledge Discovery Using Multiple Support Vector Machines

U.S. Patent No. 6,157,921
Enhancing Knowledge Discovery Using Support Vector Machines in a Distributed Network Environment

U.S. Patent No. 6,427,141
Enhancing Knowledge Discovery Using Multiple Support Vector Machines.

U.S. Patent No. 6,658,395
Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.

U.S. Patent No. 6,714,925
System for Identifying Patterns in Biological Data Using a Distributed Network.

U.S. Patent No. 6,760,715
Enhancing Biological Knowledge Discovery Using Multiple Support Vector Machines.

U.S. Patent No. 6,789,069
Method of Identifying Patterns in Biological Systems and Method of Uses.

U.S. Patent No. 6,882,990
Method of Identifying Biological Patterns Using Multiple Data Sets.

U.S. Patent No. 6,944,602
Spectral Kernels for Learning Machines

U.S. Patent No. 6,996,542
Computer-Aided Image Analysis

U.S. Patent No. 7,117,188
Methods of Identifying Patterns in Biological Systems and Uses Thereof

U.S. Patent No. 7,299,213
Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset

U.S. Patent No. 7,318,051
Methods for Feature Selection in a Learning Machine

U.S. Patent No. 7,353,215
Kernels and Methods for Selecting Kernels for Use in a Learning Machine

U.S. Patent No. 7,383,237
Computer-Aided Image Analysis

U.S. Patent No. 7,444,308
Data Mining Platform for Bioinformatics and Other Knowledge Discovery

U.S. Patent No. 7,475,048
Pre-Processed Feature Ranking for a Support Vector Machine

U.S. Patent No. 7,542,947
Data Mining Platform for Bioinformatics and Other Knowledge Discovery

U.S. Patent No. 7,542,959
Feature Selection Using Support Vector Machine Classifier

U.S. Patent No. 7,617,163
Kernels and Kernel Methods for Spectral Data

U.S. Patent No. 7,624,074
Methods for Feature Selection in a Learning Machine

U.S. Patent Publication No. 2005/0165556
Colon Cancer-Specific Markers

U.S. Application No. 11/926,129
System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source

U.S. Patent Publication No. 2008/0301070
Kernels and Methods for Selecting Kernels for Use in a Learning Machine

U.S. Patent Publication No. 2005/0071140
Model Selection for Cluster Data Analysis

U.S. Patent Publication No. 2008/0140592
Model Selection for Cluster Data Analysis

U.S. Patent Publication No. 2008/0097938
Data Mining Platform for Knowledge Discovery from Heterogeneous Data Types and/or Heterogeneous Data Sources

U.S. Patent Publication No. 2008/0097940
Kernels and Kernel Methods for Spectral Data

U.S. Patent Publication No. 2008/0233576
Method for Feature Selection in a Support Vector Machine Using Feature Ranking

U.S. Application No. 12/367,541
Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines

WIPO Application No. PCT/US09/33504
Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines

IPSCIO Record ID: 315834

License Grant
For the Licensed Technology, Licensor grants a non-exclusive license under the Licensed Technology to make, have made, use, sell, offer for sale and import Licensed Uses in the Territory in the Field.

For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study.  Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples.  Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.

For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensor’s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.

License Property
Licensor has rights in the Licensed Technology covering genomic biomarkers related to prostate cancer.  Licensor is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery.

The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.

Field of Use
Field shall mean clinical diagnostic applications using biomarkers in urine for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of in vitro diagnostic kits.

Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.

IPSCIO Record ID: 6506

License Grant
Licensor grants a non-exclusive license, with the right to grant sublicenses to Affiliates, and, upon prior approval by Licensor, to third parties under the Licensed Technology to import, make, have made, use and sell any Licensed Product with respect to both the commercial reference laboratory field and the academic and research fields.
License Property
The Parties are working on development of a new molecular diagnostic test for prostate cancer based on our discovered prostate cancer biomarker signature.

7,117,188 Method of Identifying Patterns in Biological Systems and Uses Thereof
U.S. 2007/0092917 Biomarkers for Screening, Predicting, and Monitoring Prostate Disease

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

IPSCIO Record ID: 3802

License Grant
Licensor hereby grants an exclusive license with the right to grant sublicenses to Affiliates, and, upon prior approval by Licensor, to third parties under the Licensed Technology to import, make, have made, use and sell any Licensed Product in the Field of Use within the Licensed Territory.
License Property
Licensor has certain patent rights and technology covering genomic biomarkers related to prostate cancer.

The Licensor announced an alliance and licensing Agreement with the Licensee for development of a new molecular diagnostic test for prostate cancer based on the Licensor's discovered prostate cancer biomarker signature.  The parties have successfully completed all phases of the clinical trial process with the hope of achieving the statistical significance necessary to validate the ability to commercialize a test.

The agreement covers a unique 4-gene test that may enhance the early detection and staging of prostate cancer, thereby helping doctors make better decisions on diagnosing this disease and determining more appropriate, patient specific treatment plans. Licensor will lead the research effort through the application of its patent protected SVM technology. Licensee will have a right of first refusal to license and commercialize any subsequent cancer tests resulting from licensor's development endeavors. Licensee anticipates that it will begin validation work on the cancer marker immediately and follow with appropriate clinical studies to support the preliminary findings. Once the clinical studies are completed, licensee will seek the necessary regulatory approvals and clearances.

U.S. 7,117,188 Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S. 2007/0092917 Biomarkers for Screening, Predicting, and Monitoring Prostate Disease

Field of Use
'Field of Use' shall mean diagnostic tests using gene biomarkers for differentiating clinically significant prostate cancer from other prostate conditions using biopsied prostate tissue.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.

IPSCIO Record ID: 385618

License Grant
Licensor grants Licensee, a Chinese joint venture, use of Licensed Technical Secrets to carry out businesses in the whole country, excluding Hong Kong, Macao and Taiwan regions.
License Property
Licensor is the, Clinical Laboratory Improvement Amendments of 1988 (CLIA), and, the College of American Pathologists (CAP), certified clinical molecular diagnostic gene testing service organization, with independent research and development of bio-information analysis technology, genetic database, top technical equipment and years of genetic information interpretation experience.

The Contents of licensed technical secret are Clinical molecular diagnostic gene detection technology, the corresponding software and database.

The Licensor is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Licensor has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows Licensor  to offer a broad and flexible test menu and continually expand and improve our proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times.

Field of Use
Genetic testing identifies mutations in genes or chromosomal abnormalities to confirm or rule out a suspected genetic condition or to evaluate a person’s likelihood of developing a genetic condition.

Licensee intends to carry out clinical molecular diagnostic genetic testing business.

IPSCIO Record ID: 306181

License Grant
For Biomarker IP, Licensor will grant an exclusive, perpetual, royalty-bearing license under Licensor Biomarker IP to make, have made, use, sell, offer for sale, import and otherwise exploit any and all Consumable Products, and have any and all of the foregoing performed on its behalf, in each case solely for applications other than developing and commercializing Clinical Laboratory Tests.  

This agreement has exclusive and non-exclusive territories.

License Property
Test Kit means a kit, biochip or other supply developed by Licensee pursuant to a Test Kit Development Program for an Application that corresponds to a Licensed Laboratory Test developed by Licensor and cleared or approved by the FDA or other Regulatory Authority, as relevant, for marketing in the applicable jurisdiction. A Test Kit will include components and instructions required for performing such Application.

Licensor is a leading provider of diagnostic testing, information and services and has substantial experience in the development and commercialization of products having Clinical Diagnostic Applications.

Test Kit Service means a clinical laboratory test that is performed by a member of the  Licensors Network or a Third Party using a Test Kit that has been approved or cleared by the FDA or other applicable Regulatory Authority for marketing in the applicable jurisdiction, if necessary, and has been developed by Licensee pursuant to a Test Kit Development Program.

Field of Use
This strategic alliance is to collaborate in the development and commercialization of proteomic diagnostic tests based on Licensee’s SELDI ProteinChip technology.

The ProteinChip Array technology is used for the discovery, validation, identification, and characterization of disease-associated proteins from biological samples. The versatile nature of this technology is enabling for a wide variety of applications in both research and clinical proteomics and will be reviewed in three application areas. A recent publication presents the use of the flexibility and power of the ProteinChip Array platform to elucidate the nature of novel protein inhibitors of HIV-1 replication, the molecules previously known as the CD8+ antiviral factors. Numerous cancer-related publications have demonstrated the discovery and development of biomarkers and multimarker patterns for protein-based predictive medicine.

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) represents the successful combination of retentate chromatography and mass spectrometry, and this technology is an integral part of Ciphergen's ProteinChip System, which was designed to answer biomedical questions by performing protein analyses on a single experimental platform. The quantification capability of the ProteinChip System is essential in all proteomic applications for which this technology is used. Here we describe methods and results for three short experiments mimicking realistic analytical challenges to provide practical examples of quantification.

Field means all potential Clinical Diagnostics.  Licensee develops, manufactures and markets its ProteinChip Systems using its patented surface enhanced laser desorption/ionization (SELDI) technology and also owns and operates a division directed toward the development and commercialization of products for the field of Clinical Diagnostics, including the discovery of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits.

Licensee develops, manufactures and sells ProteinChip Systems for life science researchers.  The systems consist of ProteinChip Readers, ProteinChip Software and related accessories, which are used in conjunction with consumable ProteinChip Arrays.  These products are sold primarily to biologists at pharmaceutical and biotechnology companies, and academic and government research laboratories.  The Company also provides research services primarily through its Biomarker Discovery Center® laboratories.

IPSCIO Record ID: 294268

License Grant
Licensor grants an exclusive, perpetual, worldwide license under all Licensor Biomarker IP, Licensor Collaboration IP and Licensor Platform IP to  use Instruments, and Proprietary Supplies supplied by Licensor solely to develop and commercialize such Licensed Laboratory Test; and, make, have made, use, sell, offer for sale, import and otherwise exploit any and all subject matter within the Licensor Licensed Technology that is not supplied to Licensee by Licensor hereunder or the applicable Supply Agreement or made generally commercially available to Third Parties by Licensor, in each case to develop and commercialize such Licensed Laboratory Test.

This agreement has exclusive and non-exclusive territories.

License Property
Licensor develops, manufactures and markets its Protein Chip Systems using its patented surface enhanced laser desorption/ionization (SELDI) technology and also owns and operates a division directed toward the development and commercialization of products for the field of Clinical Diagnostics, including the discovery, principally through Licensor Collaboration Agreements, of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits.

Clinical Diagnostic means, in connection with clinical medical practice, the assaying, testing, or determination outside of a living organism of one or more Biomarkers in or on any test sample for the purpose of identifying, characterizing, defining, or diagnosing a disease state or other condition in humans or animals, including without limitation determining the state of an individual’s health to treat or prevent disease as well as the screening, prognosis, therapeutic monitoring, and/or evaluation of the progression of any disease or other condition.

Biomarker means any
—  nucleic acid (whether DNA, RNA or otherwise), protein or organic molecule;
—  set of nucleic acids, proteins and/or organic molecules or
—  profile, i.e., presence and/or quantity, of the items described.  As used herein, the term protein refers to any polypeptide and the term nucleic acid refers to any nucleotide sequence, in either case whether naturally occurring, synthesized, modified or otherwise.

The patents relate to cancers and heart disease.

Field of Use
Field means all potential Clinical Diagnostics.   Licensor products are for the field of Clinical Diagnostics, including the discovery of disease-specific Biomarkers and protein signatures that could be utilized in Licensed Laboratory Tests and Test Kits .

Licensee is a provider of diagnostic testing, information and services and has substantial experience in the development and commercialization of products having Clinical Diagnostic Applications.  This alliances activities are directed toward discovery of Biomarkers for Clinical Diagnostic applications, and, modifications to the Licensors Platform Technology to meet the requirements of the Clinical Diagnostics markets and FDA.

IPSCIO Record ID: 26038

License Grant
The Licensor grants to Licensee a non-exclusive right and license, without the right to sublicense, under the Licensed Patent Rights as licensed to Licensor pursuant to the Original Agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice the Licensed Methods in the Field in the Territory to the extent permitted by law.
License Property
The Licensor is involved in the discovery, development and commercialization of medical tests that diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. Field shall mean in-vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.
Field of Use
The Licensee is a provider of clinical laboratory services.

Field” shall mean in vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.

IPSCIO Record ID: 4690

License Grant
The Licensee agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology.
License Property
The non-exclusive license is to a worldwide portfolio of patents and patent applications directed to Diagnosis and Prognosis of Breast Cancer Patients (e.g., claiming priority to U.S. Provisional Patent Nos. 60/298918 and/or 60/380710) in the fields of research, diagnosis, prognosis and/or prediction of therapeutic outcome or risk for humans or animals in the area of oncology.

IPSCIO Record ID: 273391

License Grant
Licensor hereby grants to Licensee, subject to all the terms and conditions of this Agreement, a worldwide, nonexclusive right and license (without the right to grant sublicenses) under the Patent Rights to (a) use, offer to sell, sell and practice Diagnostic Services in the Field; (b) make, have made, use, offer to sell, sell and import Licensed Reagents in the Field; and (c) make, have made, use, offer to sell, sell and import Kits in the Field. Notwithstanding the foregoing, Licensor hereby grants to Licensee the worldwide, non-exclusive right to convey to the end-user (purchaser) of FDA (U.S. Food and Drug Administration) Approved Kits manufactured by Licensee the right to perform Diagnostic Services solely in conjunction with the use of FDA Approved Kits manufactured by or on behalf of Licensee (without the right to grant sublicenses).
License Property
Patent Rights shall mean collectively the Gene Patent Rights and the Methodology Patent Rights.

Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

Gene Patent Rights shall mean the United States and foreign patents and patent applications relating to the APC (Adenomamus polyposis coli) gene and/or the p53 gene and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents arising therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent applications listed hereto (which may be updated from time to time to include such additional patents and patent application that may arise therefrom); provided, however, that Gene Patent Rights expressly excludes any claims of such patents and patent applications that fall outside of the Field, including, without limitation, claims to antibodies, to the treatment, prevention or remedying of a gene deficiency, to purified proteins, or to DNA (Deoxyribonucleic acid) sequences other than those sequences that correspond to the p53 gene and the APC (Adenomatous polyposis coli) gene; provided further that DNA sequences which are (i) immediately adjacent to the p53 or APC genes and (ii) necessary to the use of the p53 or APC genes, respectively, in the Field shall be considered within the Gene Patent Rights.

US Patent No.  5,352,775 – APC gene and nucleic acid probes derived therefrom
US Patent No.  5,527,676 – Detection of loss of the wild-type P53 gene and kits therefor

Methodology Patent Rights shall mean the United States and foreign patents and patent applications relating to methods of detecting mammalian nucleic acids isolated from stool specimens and reagents therefor and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents resulting therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent application listed hereto (which may be updated from time to time to include such additional patents and patent applications that may arise therefrom).

US Patent Application No. W093/20235 and 08/861,910 (detecting mammalian nucleic acids from stool)

Licensed Reagent shall mean any Reagent covered in whole or in part by a Valid Claim of the Patent Rights.

Kit shall mean a collection of one or more Reagents, including at least one Licensed Reagent, packaged in the form of a kit (including an FDA Approved kit).

Field of Use
Field shall mean (a) stool-based detection of any disease or condition (including pre-cancers, staging and monitoring of the foregoing, and therapeutic response) for research and development, Clinical Laboratory Improvement Amendments (CLIA) testing services (and their foreign equivalents), and FDA Approved Kits; and (b) a screening assay (regardless of other uses to which such assay is put) for colorectal cancer in any type of patient samples, excluding tests solely for staging and/or monitoring of colorectal cancer which do not obsolete or adversely impact such screening assay.

IPSCIO Record ID: 26489

License Grant
The Company hereby grants to Licensee an exclusive, worldwide, royalty-bearing, limited license under the Licensed Technology to make, have made, import, use, sell and have sold the Devices solely within the Field of Use.
License Property
U.S. 5,860,934                    Method and Device for Mechanical Imaging of Breast         Issued 01/19/99

(CIP of App. 07/994,109)

U.S. 5,833,633                    Device for Breast Haptic Examination                       Filed 11/03/97

(CIP of 5,524,636)                                                                           Issued 11/10/98

U.S. 5,785,633                    Method and Device for Mechanical Imaging of Prostate       Filed 02/27/96

(CIP of 5,524,636)                                                                           Issued 07/28/98

U.S. 5,836,894                    Apparatus for Measuring Mechanical Parameters of the       Filed 06/10/97

(CIP of 5,524,636)                Prostate and for Imaging the Prostate Using such           Issued 11/17/98

U.S. 5,922,018                    Method for Using a Transrectal Probe to Mechanically        Filed 06/10/97

(CIP of 5,524,636)                Image the Prostate Gland                                    Issued 07/13/99

U.S. 5,524,636                    Method and Apparatus for Elasticity Imaging                Filed 12/21/92

U.S. 5,265,612                    Intracavity Ultrasonic Device for Elasticity Imaging       Filed 12/21/92

U.S. 6,142,959                    Device for Palpation and Mechanical Imaging of the         Filed 07/22/99

                                  Prostate                                                   Issued 11/07/00

PCT/US00/19756                    Device for Palpation and Mechanical Imaging of the         Filed 07/21/00

                                  Prostate

U.S. 09/843,056                   Apparatus and Method for Mechanical Imaging of Breast      Filed 04/26/01

PCT/US01/13551                    Apparatus and Method for Mechanical Imaging of Breast      Filed 4/26/01

U.S. 60/200,433                   Apparatus and Method for Mechanical Imaging of Breast      Filed 4/28/00

U.S. 09/819,419                   Real Time Mechanical Imaging of the Prostate               Filed 03/28/01

Field of Use
Field of Use shall mean the diagnosis of and the treatment of (a) benign prostatic hyperplasia; (b) prostatitis; © prostate cancer; or (d) any other conditions of or disorders of the prostate, whether healthy or diseased, and any other condition of urologic disorder which may be diagnosed, imaged or treated using any diagnostic or imaging process.  Prostate imaging system and related patented technology.

IPSCIO Record ID: 5622

License Grant
The Licensor hereby grants an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to (a) confirm performance of the Colon 101 ELISA Test and (b) use the Colon 101 ELISA Test to offer and provide services within the cDx Field and the rDx Field.

Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.

CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

The Licensee shall have the right to use the Trademarks.

License Property
The Licensor has developed a blood test known as the Colon 101 ELISA Test  to detect and quantify the Colon 101 protein in serum.
Field of Use
'CDX Field' means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.

IPSCIO Record ID: 28487

License Grant
The Licensor granted the Licensee a non-exclusive license agreement for the use of the patent rights and technology as they relate to cervical and ovarian cancer.
License Property
The Company agreed to settle an arbitration proceeding instituted by anther party against the Company through the transfer to the other party of certain patents, patent applications and other intellectual property rights relating to the AcCell technology.

The AcCell product is a computer-aided automated microscopy instrument designed to help medical specialists examine and diagnose specimens of human cells.

U.S. Patent 6,535,626; 6,430,309; 6,285,498; 6,148,096; 6,151,161; 6,118,581; 6,091,842; 6,081,740; 5,999,844; 5,963,368; 5,930,732; 5,833,794; 5,690,892; 5,077,806; 5,073,857

Field of Use
Licensed Field shall mean the field of products designed, developed, tested, manufactured, distributed, marketed, approved, sold, provided, and/or used exclusively for the screening of cervical or ovarian cancer which require the incorporation of  a fluorescent probe as its primary probe,  or which may incorporate other fluorescent or non-fluorescent probes, and in which the assay itself (a procedure employing one or more reagents which determines the biological state of a clinical specimen comprised of cells or tissues) is primarily fluorescent.

Licensee have designed and manufactured the AcCell(TM) computer-aided automated microscopy instrument and the AcCell Savant(TM), an instrument that includes an AcCell instrument and software and which collects quantitative cellular information used in support of a diagnostic process.

Licensee is a life sciences company engaged in the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.